Skip to main content
HIKMA Pharmaceuticals PLC logo

HIKMA Pharmaceuticals PLC — Investor Relations & Filings

Ticker · HIK ISIN · GB00B0LCW083 LEI · 549300BNS685UXH4JI75 IL Manufacturing
Open in API
Filings indexed 827 across all filing types
Latest filing 2025-05-15 Earnings Release
Country GB United Kingdom
Listing IL HIK

About HIKMA Pharmaceuticals PLC

https://www.hikma.com/home/

Hikma Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and markets a broad portfolio of pharmaceutical products. The company's offerings include a wide range of generic, branded, specialty, and in-licensed medicines. It is a significant supplier of generic injectable products to hospitals and also provides oral generics and other specialty medications. With a focus on producing high-quality medicines, Hikma aims to make its products accessible to patients and healthcare providers across its key markets in North America, Europe, and the Middle East & North Africa (MENA) region.

Recent filings

Filing Released Lang Actions
Medium-term Group guidance ahead of US site visit
Earnings Release Classification · 99% confidence The document is identified by the 'RNS Number' header and contains an announcement from Hikma Pharmaceuticals Plc dated May 15, 2025. The content describes an event (US site visit) where the company is presenting business strategies and introducing medium-term guidance (revenue growth CAGR, operating profit growth CAGR, and a 5-year revenue target). This is a corporate announcement disseminated via RNS, the news service of the London Stock Exchange. Since it is an announcement providing key updates and guidance, and not a full financial report (like 10-K or IR), it fits best under the general 'Regulatory Filings' category (RNS) as it is a formal regulatory dissemination that doesn't match a more specific category like ER (Earnings Release, which usually contains actual period results) or IP (Investor Presentation, which is usually the deck itself, though this announcement references one). Given the nature of the RNS distribution and the content being a strategic update/guidance announcement, RNS is the most appropriate general regulatory filing code. FY 2025
2025-05-15 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a formal notification of share acquisitions by Persons Discharging Managerial Responsibility (PDMRs) under the EU Market Abuse Regulation (MAR). It explicitly lists the names of the individuals, their positions, the nature of the transaction (dividend reinvestment plan), and the specific details of the share purchases. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2025-05-08 English
S&P upgrades Hikma to ‘BBB’
Regulatory Filings Classification · 100% confidence The document is a short announcement released via RNS (RNS Number : 8970H) on May 8, 2025. The content explicitly details a credit rating upgrade by S&P ('BBB' from 'BBB-') for Hikma Pharmaceuticals Plc and its Senior Notes. This is a general, material corporate announcement that does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA). Since it is a formal, non-standard regulatory announcement distributed via the London Stock Exchange's news service (RNS), and it doesn't fit a more specific category like Interest Rate Update (IRAT) or Capital Update (CAP), the most appropriate classification is the general Regulatory Filings category (RNS). The document length is short (3689 chars) and it is a direct announcement, not an attachment or a full report.
2025-05-08 English
Settlement agreement for Xyrem® US lawsuits
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 8679H' and is dated May 8, 2025. It announces a settlement agreement regarding class action lawsuits (Xyrem® antitrust cases) and provides contact details for Investor Relations and Press. The presence of the RNS header, the nature of the announcement (a specific corporate event/legal update), and the concluding boilerplate text from RNS (London Stock Exchange's news service) strongly indicate this is a regulatory news service announcement. Since it is a specific announcement that doesn't fit perfectly into categories like ER, CT, or LTR (though it relates to legal matters, it's a resolution announcement), and it is clearly distributed via RNS, the most appropriate classification is the general regulatory filing category, RNS, as it is a standard regulatory news wire release.
2025-05-08 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly mentions 'RNS, the news service of the London Stock Exchange'. The content details transactions (grant of a pledge over shares) by 'Persons Discharging Managerial Responsibilities ("PDMRs")' and cites compliance with 'Article 19(1) of the EU Market Abuse Regulation ("MAR")'. This structure is characteristic of mandatory regulatory disclosures concerning insider transactions. The specific filing type that covers personal share transactions by directors and executives is 'Director's Dealing' (DIRS). Although it is distributed via RNS, the core content is DIRS.
2025-04-30 English
Group of companies' accounts made up to 2024-12-31
Regulatory Filings
2025-04-30 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.